Phase II evaluation of ifosfamide plus doxorubicin and filgrastim versus gemcitabine plus docetaxel and filgrastim in the treatment of localized poor prognosis soft tissue sarcoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Docetaxel; Doxorubicin; Gemcitabine; Ifosfamide
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 07 Dec 2015 Biomarkers information updated
- 04 Jun 2013 Interim results presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
- 04 Jun 2013 Trial rationale and design presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).